GetTopicDetailResponse(id=103d3692a8, topicName=BRCA1或BRCA2突變, introduction=BRCA1或BRCA2突變, content=null, image=null, comments=1, allHits=618, url=https://h5.medsci.cn/topic?id=3692, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=98870, tagList=[TagDto(tagId=98870, tagName=BRCA1或BRCA2突變)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1780466, encodeId=9b2e1e80466af, content=<a href='/topic/show?id=103d3692a8' target=_blank style='color:#2F92EE;'>#BRCA1或BRCA2突變#</a>, objectTitle=英國NICE批準(zhǔn)將PARP抑制劑Lynparza，用于BRCA1或BRCA2突變的鉑敏感型卵巢癌、輸卵管癌或腹膜癌復(fù)發(fā)患者, objectType=article, longId=186454, objectId=6fbf186454dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf186454dd, replyNumber=0, likeNumber=98, createdTime=2020-11-17, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf186454dd, moduleTitle=英國NICE批準(zhǔn)將PARP抑制劑Lynparza，用于BRCA1或BRCA2突變的鉑敏感型卵巢癌、輸卵管癌或腹膜癌復(fù)發(fā)患者, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6fbf186454dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
